Sign Out
Use in Pregnancy: No teratogenic effects attributable to Optiray (ioversol) have been observed to date in studies performed in animals. There are no studies on the use of Optiray in pregnant women. Many injectable contrast media cross the placental barrier in humans and appear to enter fetal tissue passively. Optiray probably crosses the placental barrier in humans by simple diffusion to reach fetal tissue. Optiray should be used during pregnancy only if the benefit to the mother clearly outweighs the risk to the fetus. It should be borne in mind that X-ray procedures involve a certain risk related to exposure of the fetus.
Use in Lactation: Because contrast media are secreted in human milk, if the administration of Optiray is considered to be essential, breast feeding should be discontinued for at least 48 hours following the procedure.
